La vendita allo scoperto per Galecto dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Galecto. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Galecto (NASDAQ:GLTO) Azioni, Report sulle vendite allo scoperto

Galecto

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Galecto Inc

News

Guidance

SDRL

Seadrill Affirms FY2025 Sales Guidance of $1.30B-$1.36B vs $1.36B Est

Earnings

Earnings Beats

Earnings Misses

Seadrill Q1 EPS $(0.23) Misses $0.60 Estimate, Sales $335.00M Beat $334.54M Estimate

<ul>
<li>Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).</li>
<li>The ‘782 patent, which issued on June 14, 2022, arises out of the same patent family as U.S. Patent No. 10,716,793 (the ‘793 patent) and claims the same general method of administering inhaled treprostinil to pulmonary hypertension patients. As disclosed in July 2022, the ‘793 patent was held to be invalid in a proceeding before the Patent Trial and Appeal Board (PTAB). The PTAB's decision was affirmed by the&nbsp;U.S. Court of Appeals for the Federal Circuit&nbsp;in&nbsp;December 2023. The United States Supreme Court&nbsp;rejected UTHR's petition for a writ of certiorari, thereby upholding PTAB's decision which found that all claims of the ‘793 patent are unpatentable due to prior art as final and not subject to further appeal.</li>
<li>UTHR is currently not seeking any injunction against the FDA to prevent final approval of the New Drug Application (NDA) for YUTREPIA. As previously announced, the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.</li>
</ul>

Biotech

Health Care

Legal

General

LQDA

UTHR

United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.walkerdunlop.com%2F&amp;esheet=54252815&amp;newsitemid=20250512455389&amp;lan=en-US&amp;anchor=Walker+%26amp%3B+Dunlop%2C+Inc.&amp;index=1&amp;md5=1495e66b29aae4d37b0eaffd41071612">Walker &amp; Dunlop, Inc.</a> is celebrating the ground breaking of Parkside 5, the fifth and final phase of the Parkside at Old Town development, a 99-unit community located on the former Cabrini-Green public housing site in Chicago's Near North Side.
&nbsp;
&nbsp;
Parkside 5 Groundbreaking. (Photo courtesy of Holsten Real Estate Development Corp.)
The Walker &amp; Dunlop affordable housing team, led by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.walkerdunlop.com%2Fabout%2Fpeople%2Fjen-erixon&amp;esheet=54252815&amp;newsitemid=20250512455389&amp;lan=en-US&amp;anchor=Jennifer+Erixon&amp;index=2&amp;md5=3497114b7444654b189ea95a93a6c8ae">Jennifer Erixon</a>, syndicated Low Income Housing Tax Credits (LIHTC) and Illinois Donation Tax Credits on behalf of the client, Holsten Real Estate Development Corporation. Walker &amp; Dunlop Affordable Equity syndicated the equity to JP Morgan, resulting in $22.6 million of equity to support the development. In addition to syndicating the credits, JP Morgan is also providing a construction loan for the project.
The funding will support the construction of a mix of market-rate and affordable units, with 37 of the units benefiting from a 20-year Section 8 Housing Assistance Payment (HAP) contract. These affordable units will be reserved for households earning 50% and 60% of the area median income (AMI) or less. "We are proud to support the continued revitalization of the Near North Side, helping to bring much-needed affordable housing options to the community while contributing to the broader transformation of the former Cabrini-Green site," said Jennifer Erixon, senior managing director of Affordable Equity Originations at Walker &amp; Dunlop. "Our partners at Holsten have allowed us to provide a valuable solution that meets our shared goals."
Parkside 5 will feature three 3-story walk-up buildings and an 8-story mid-rise structure with townhome units at its base. Planned amenities include a community room, fitness center, and onsite social services for residents. Additionally, a playground, and dog park, will be open to the community to position Parkside 5 as a vibrant, inclusive space for its residents and neighbors. The development will complement the existing phases of the Parkside at Old Town project, a key piece in the ongoing revitalization of the historic neighborhood.

Final Phase of Chicago's Cabrini-Green Revamp Breaks Ground With 99 New Homes, Backed by Walker & Dunlop

Canlan Ice Sports (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ICE#TSX">ICE</a>) reported quarterly earnings of $0.32 per share. This is unchanged from the same period last year. The company reported $27.98 million in sales this quarter. This is a 6.85 percent increase over sales of $26.19 million the same period last year.

TSX:ICE

Canlan Ice Sports Q1 EPS $0.32, Same YoY, Sales $27.98M Up From $26.19M YoY

<ul>
<li>Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%</li>
<li>APG808 demonstrated the potential for durable disease control in asthma with sustained FeNO decrease from baseline of 50% at 12 weeks</li>
<li>APG808's optimized formulation and potential best-in-class pharmacokinetic (PK) profile, combined with robust and sustained FeNO suppression through 12 weeks, support the potential for transformative dosing every 2-months or longer, compared to the current biweekly standard of care</li>
<li>APG808 was well tolerated with a favorable safety profile consistent with the anti-IL-4Rα class</li>
<li>Phase 1b proof-of-concept data validates Apogee's approach to designing potentially best-in-class biologics and builds on Apogee's track record of execution</li>
</ul>

APGE

Apogee Therapeutics Released Interim Data From Its Phase 1b Trial Of APG808, A Novel Half-life Extended IL-4Rα Antibody, In Patients With Mild-to-moderate Asthma

Vertical Aerospace ("Vertical") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) today announced it is developing a hybrid-electric vertical-take-off-and landing (VTOL) variant of its VX4 aircraft, expanding range and payload capabilities to unlock new market opportunities within the already sizable $1TR1 total addressable urban air mobility market.
&nbsp;
&nbsp;
Vertical's second-generation hybrid-propulsion system, which has been in development for 18 months at the Vertical Energy Centre
Vertical's hybrid-electric strategy builds on its all-electric VX4 and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvertical-aerospace.com%2Fwp-content%2Fuploads%2F2024%2F11%2FVertical-Aerospace-Launches-Flightpath-2030-a-strategy-to-pioneer-electric-aviation.pdf&amp;esheet=54252992&amp;newsitemid=20250512888129&amp;lan=en-US&amp;anchor=Flightpath+2030+strategy&amp;index=1&amp;md5=4ff01c56d06d0d49334fe4ce9c9c11f4">Flightpath 2030 strategy</a>, enabling new potential applications in defence, logistics and commercial sectors including air ambulance services, which require longer range and higher payload than current eVTOL platforms can deliver.
Vertical's second-generation hybrid-propulsion system, which has been in development for 18 months at the Vertical Energy Centre, will be retrofitted into one of the company's VX4 full scale prototypes and is expected to commence flight testing in Q2 2026.

EVTL

Vertical Aerospace Unveils Hybrid Air Taxi to Boost Range, Targeting $1T Urban Air Mobility Market

<ul>
<li>Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling</li>
<li>First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026</li>
<li>APG279 on track to initiate Phase 1b head-to-head trial vs DUPIXENT in 2025 with readout expected in 2H 2026</li>
<li>Positive interim Phase 1b readout of APG808 in patients with mild-to-moderate asthma demonstrated rapid, robust and sustained suppression of FeNO, a biomarker of Type 2 inflammation that is associated with exacerbations in asthma</li>
</ul>

Apogee Therapeutics Cash, Cash Equivalents And Marketable Securities Were $681.4M As Of March 31, 2025 That Supports Runway Into Q1 2028

Allot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.05) by 140 percent. This is a 166.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $23.20 million which beat the analyst consensus estimate of $20.20 million by 14.85 percent. This is a 5.98 percent increase over sales of $21.89 million the same period last year.

ALLT

Allot Q1 Adj. EPS $0.02 Beats $(0.05) Estimate, Sales $23.20M Beat $20.20M Estimate

ORLA

Orla Mining Q1 Adj. EPS $0.12 Beats $0.10 Estimate, Sales $140.67M Miss $163.19M Estimate

Keybanc analyst Steve Barger upgrades Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) from Sector Weight to Overweight and announces $110 price target.

Upgrades

Price Target

Analyst Ratings

Keybanc Upgrades Federal Signal to Overweight, Announces $110 Price Target

Rumors

Tech

AAPL

The Wall Street Journal Reported Apple Is Weighing Fall iPhone Price Increases; Won't Attribute Hikes to Tariffs

OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) reported quarterly sales of $45.70 million which beat the analyst consensus estimate of $42.28 million by 8.08 percent. This is a 63.69 percent increase over sales of $27.92 million the same period last year.

OrganiGram Holdings Q2 Sales $45.70M Beat $42.28M Estimate

Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>), a company developing electric air taxis for commercial passenger service, today announced it has successfully flown two of its aircraft simultaneously for the first time, marking another important milestone in the Company's flight testing program.
&nbsp;
&nbsp;
Two Joby air taxis (N541JX and N544JX) flying simultaneously in the skies over Marina, CA. Joby Aviation photo
The two-aircraft flight, completed in Marina, CA, on May 9, is a further demonstration of the maturity of Joby's test program, and comes just two weeks after the Company announced it had reached another testing landmark, successfully completing flights with a full transition from vertical to cruise flight, and back again, with a pilot onboard.

JOBY

Joby Aviation Flies Two Air Taxis Together for First Time, Marking Major Leap Toward Commercial Launch

EVEX

Eve Holding Q1 EPS $(0.16) Misses $(0.14) Estimate

GUIDANCE
Rockwell confirms its 2025 annual guidance as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2025 Annual Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">$65.0M to $70.0M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">16% to 18%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">($0.5)M to $0.5M</td>
</tr>
</tbody>
</table>
</figure>

RMTI

Rockwell Medical Affirms FY2025 Sales Guidance of $65.00M-$70.00M vs $67.42M Est

Aurinia Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) affirms FY2025 sales outlook from $250.00 million-$260.00 million to $250.00 million-$260.00 million vs $257.87 million estimate.

AUPH

Aurinia Pharmaceuticals Affirms FY2025 Sales Guidance of $250.00M-$260.00M vs $257.87M Est

Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.51) by 31.37 percent. This is a 48.89 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $130.44 million which missed the analyst consensus estimate of $139.55 million by 6.53 percent. This is a 4.10 percent decrease over sales of $136.02 million the same period last year.

CNTY

Century Casinos Q1 EPS $(0.67) Misses $(0.51) Estimate, Sales $130.44M Miss $139.55M Estimate

Hudbay Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBM#NYSE">HBM</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.12 by 100 percent. This is a 41.18 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $594.50 million which beat the analyst consensus estimate of $573.89 million by 3.59 percent. This is a 13.24 percent increase over sales of $524.99 million the same period last year.

Hudbay Minerals Q1 Adj. EPS $0.24 Beats $0.12 Estimate, Sales $594.50M Beat $573.89M Estimate

Hudbay Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HBM#TSX">HBM</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.11 by 118.18 percent. This is a 50 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $594.90 million which beat the analyst consensus estimate of $521.50 million by 14.07 percent. This is a 13.32 percent increase over sales of $524.99 million the same period last year.

Comments

Galecto

Vendite allo scoperto

Galecto (NASDAQ:GLTO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO